Myriad Genetics Appoints Ben Wheeler as CFO

By Ahmed Jameison • Monday, August 18 15:38 • Permanent Link

Myriad Genetics, Inc. has announced the appointment of Ben Wheeler as the new Chief Financial Officer, effective August 16, 2025. Wheeler, who has been with the company for more than 13 years, brings extensive knowledge of the business, strong financial expertise, and proven leadership to the role.

Scott Leffler, the previous Chief Financial Officer, will transition to a consulting role serving the CEO and the board of directors through September 2, 2025.

The company is reaffirming its financial guidance for the full-year 2025, as announced during its second quarter 2025 earnings call on August 5, 2025.

Additionally, Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, aiming to advance health and well-being through the development and offering of molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions.

The financial metrics for the second quarter of 2025 were not provided in the press release. Today the company's shares have moved 3.24% to a price of $5.895. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.